TY  - JOUR
AU  - Mandala, Mario
AU  - Larkin, James
AU  - Ascierto, Paolo Antonio
AU  - Del Vecchio, Michele
AU  - Gogas, Helen
AU  - Cowey, C Lance
AU  - Arance, Ana
AU  - Dalle, Stéphane
AU  - Schenker, Michael
AU  - Grob, Jean-Jacques
AU  - Chiarion-Sileni, Vanna
AU  - Marquez-Rodas, Ivan
AU  - Butler, Marcus O
AU  - Di Giacomo, Anna Maria
AU  - Lutzky, Jose
AU  - De La Cruz-Merino, Luis
AU  - Atkinson, Victoria
AU  - Arenberger, Petr
AU  - Hill, Andrew
AU  - Fecher, Leslie
AU  - Millward, Michael
AU  - Khushalani, Nikhil I
AU  - de Pril, Veerle
AU  - Lobo, Maurice
AU  - Weber, Jeffrey
PY  - 2021
DO  - 10.1136/jitc-2021-003188
UR  - http://hdl.handle.net/10668/18479
T2  - Journal for immunotherapy of cancer
AB  - Several therapeutic options are now available in the adjuvant melanoma setting, mandating an understanding of their benefit‒risk profiles in order to make informed treatment decisions. Herein we characterize adjuvant nivolumab select (immune-related)...
LA  - en
KW  - adjuvants
KW  - immunologic
KW  - immunotherapy
KW  - melanoma
KW  - programmed cell death 1 receptor
KW  - Aged
KW  - Disease-Free Survival
KW  - Female
KW  - Humans
KW  - Immune Checkpoint Inhibitors
KW  - Melanoma
KW  - Neoplasm Staging
KW  - Nivolumab
KW  - Treatment Outcome
TI  - Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival.
TY  - research article
VL  - 9
ER  -